Leukemia, Hairy Cell Clinical Trial
Official title:
A Pivotal Multicenter Trial of Moxetumomab Pasudotox in Relapsed/ Refractory Hairy Cell Leukemia
Background:
- Moxetumomab pasudotox is an experimental non-chemotherapy cancer treatment drug. It targets
CD22, a molecule on the surface of essentially all hairy cell leukemia cells. Moxetumomab
pasudotox binds to CD22, goes into the cell, and releases a toxin which kills the cell. In a
phase I trial it had activity in relapsed/refractory hairy cell leukemia with safety profile
supporting further clinical study (http://ncbi.nlm.nih.gov/pubmed/22355053). This is a phase
III multicenter trial designed to confirm these results.
Background:
- Hairy cell leukemia (HCL) is an indolent B-cell leukemia comprising 2% of all leukemias,
or approximately 900 of the 44,000 new cases of leukemia/year in the US
- Over the last two decades, immunotoxin research has accumulated to support a role for
CD22-targeted therapy in the treatment of HCL.
- Moxetumomab pasudotox is a recombinant immunotoxin containing an Fv fragment of an
anti-CD22 monoclonal antibody and truncated Pseudomonas exotoxin.
- Moxetumomab pasudotox has demonstrated a high complete response (CR) rate in patients
with chemoresistant HCL and has shown activity in pediatric acute lymphoblastic leukemia
as well.
- Modification of the structure of moxetumomab pasudotox has greatly improved binding and
cytotoxicity toward CD22 expressing malignant cells compared to the precursor molecule.
Preclinical and clinical studies have demonstrated that this increase in binding
affinity results in improved antitumor activity and tolerability
- Currently there are no approved agents with significant efficacy for HCL patients after
failure of standard therapy
Design:
- This is a multicenter, single-arm study of moxetumomab pasudotox in patients with
relapsed/refractory hairy cell leukemia.
- 77 patients will be enrolled to receive moxetumomab pasudotox intravenously (IV) on days
1, 3 and 5 of each 28 day cycle for a maximum of 6 cycles or until disease progression,
unacceptable toxicity occurs, the subject begins alternate therapy, or documented CR
(for subjects who have no assessable minimal residual disease and not to exceed 6
cycles). If less than or equal to 2 of the first 25 patients do not achieve durable CR,
no additional patients will be accrued.
- The overall IRB accrual ceiling is currently set at 80 to allow for a small number of
patients that cannot be assessed for response.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00861510 -
A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With Relapsed Mantle Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, and Related Lymphoid Malignancies
|
Phase 1 | |
| Recruiting |
NCT05362773 -
A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies
|
Phase 1 | |
| Active, not recruiting |
NCT03410875 -
A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia
|
Phase 2 |